1. Home
  2. GBIO vs PZC Comparison

GBIO vs PZC Comparison

Compare GBIO & PZC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GBIO
  • PZC
  • Stock Information
  • Founded
  • GBIO 2016
  • PZC 2002
  • Country
  • GBIO United States
  • PZC United States
  • Employees
  • GBIO N/A
  • PZC N/A
  • Industry
  • GBIO Biotechnology: Pharmaceutical Preparations
  • PZC Investment Managers
  • Sector
  • GBIO Health Care
  • PZC Finance
  • Exchange
  • GBIO Nasdaq
  • PZC Nasdaq
  • Market Cap
  • GBIO 166.2M
  • PZC 163.2M
  • IPO Year
  • GBIO 2020
  • PZC N/A
  • Fundamental
  • Price
  • GBIO $2.66
  • PZC $7.52
  • Analyst Decision
  • GBIO Buy
  • PZC
  • Analyst Count
  • GBIO 4
  • PZC 0
  • Target Price
  • GBIO $7.50
  • PZC N/A
  • AVG Volume (30 Days)
  • GBIO 74.3K
  • PZC 48.2K
  • Earning Date
  • GBIO 11-07-2024
  • PZC 01-01-0001
  • Dividend Yield
  • GBIO N/A
  • PZC 4.68%
  • EPS Growth
  • GBIO N/A
  • PZC N/A
  • EPS
  • GBIO N/A
  • PZC N/A
  • Revenue
  • GBIO $13,174,000.00
  • PZC N/A
  • Revenue This Year
  • GBIO $99.36
  • PZC N/A
  • Revenue Next Year
  • GBIO N/A
  • PZC N/A
  • P/E Ratio
  • GBIO N/A
  • PZC N/A
  • Revenue Growth
  • GBIO 1397.05
  • PZC N/A
  • 52 Week Low
  • GBIO $0.86
  • PZC $6.30
  • 52 Week High
  • GBIO $4.65
  • PZC $8.20
  • Technical
  • Relative Strength Index (RSI)
  • GBIO 53.38
  • PZC 74.29
  • Support Level
  • GBIO $2.41
  • PZC $7.26
  • Resistance Level
  • GBIO $2.63
  • PZC $7.29
  • Average True Range (ATR)
  • GBIO 0.22
  • PZC 0.06
  • MACD
  • GBIO 0.03
  • PZC 0.02
  • Stochastic Oscillator
  • GBIO 64.81
  • PZC 89.39

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

About PZC PIMCO California Municipal Income Fund III of Beneficial Interest

PIMCO CA Muni Income Fund III operates as a closed-end management investment company. The investment objective of the fund is to seek to provide current income exempt from federal and California income tax. Its portfolio of investments includes investment in different sectors such as education, healthcare, industrial and others.

Share on Social Networks: